The OncLive Immunotherapy in GU Cancers condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in genitourinary malignancies, specifically prostate cancer, urothelial carcinoma, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
May 6th 2024
The FDA has accepted a biologics license application for subcutaneous nivolumab for adult patients eligible for approved solid tumor nivolumab indications.
Dr. Agarwal on Toxicities With Checkpoint Inhibitors in RCC
January 20th 2017Neeraj Agarwal, associate professor in the Division of Oncology, Department of Medicine, director of the Genitourinary Medical Oncology Program, Huntsman Cancer Institute at the University of Utah, discusses some of the adverse events (AEs) associated with checkpoint inhibitors for the treatment of patients with renal cell carcinoma (RCC).
Dr. McDermott on VEGF Plus PD-1 in Renal Cell Carcinoma
January 14th 2017David F. McDermott, MD, Director of Biologic Therapy and Cutaneous Oncology Programs, Hematology and Oncology at the Beth Israel Deaconess Medical Center, discusses the combination of VEGF plus PD-1 in renal cell carcinoma (RCC).
FDA Grants Atezolizumab Priority Review for Second Bladder Cancer Indication
January 10th 2017The FDA has granted a priority review to a supplemental new drug application for the use of the PD-L1 inhibitor atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring ≥12 months after neoadjuvant or adjuvant chemotherapy.
Amid Explosion of Novel Agents, Chemo Could Still Have Curative Role in Urothelial Carcinoma
December 15th 2016Even with 1 FDA approval of an immunotherapeutic agent in urothelial carcinoma—and more expected in the coming months—chemotherapy regimens will continue to play a pivotal part in the treatment of patients with this disease.
Additional Research Required for Immunotherapy to Replace Chemo in Upfront Bladder Cancer Care
December 13th 2016Immunotherapy may be having a moment in the changing landscape of bladder cancer, but expert Gopa Iyer, MD, advises that there is much research to be done before physicians replace chemotherapy with these agents upfront.
FDA Grants Priority Review to Durvalumab in Bladder Cancer
December 10th 2016The FDA has granted a priority review to a biologics license application for the PD-L1 inhibitor durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum‑based chemotherapy.
Dr. Rosenberg on Immunotherapeutic Advances in Bladder Cancer
November 30th 2016Jonathan E. Rosenberg, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the emergence of immunotherapies in the field of bladder cancer, including atezolizumab (Tecentriq), nivolumab (Opdivo), and pembrolizumab (Keytruda). Rosenberg shared this at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.
Dr. Iyer on Advice for Physicians Using Immunotherapy in Bladder Cancer
November 18th 2016Gopa Iyer, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses significant points for community oncologists to be aware of when treating patients with bladder cancer with immunotherapy agents.
Nivolumab/Ipilimumab Combo Highly Effective for Pretreated Metastatic Urothelial Carcinoma
The combination of nivolumab and ipilimumab led to a high response rate and improved overall survival versus historical controls for patients with pretreated metastatic urothelial carcinoma.
Dr. Plimack on Significance of CheckMate-025 Trial in RCC
November 5th 2016Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses updated findings from the CheckMate-025 trial, which compared the efficacy of nivolumab (Opdivo) with everolimus (Afinitor) in patients with renal cell carcinoma.
Dr. Mohammed Haseebuddin on Expanding Role for Immunotherapy in RCC
November 3rd 2016Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discuses why continued research into immunotherapy in clear cell renal cell carcinoma (RCC) is important, particularly in the adjuvant and neoadjuvant settings.
Dr. Pal on Sequencing Challenges for the Treatment of Patients With RCC
November 3rd 2016Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the challenges with sequencing the therapies available for patients with renal cell carcinoma (RCC). Pal shared this insight in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.
Dr. Gerritsen on Shortcomings of Immunotherapy in Prostate Cancer
October 26th 2016Winald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses some of the recent shortcomings seen with immunotherapy agents in the treatment of patients with castration-resistant prostate cancer.
Immunotherapy Emerges as Alternative to Surgery in BCG-Refractory Bladder Cancer
October 18th 2016Surgical treatment of patients with non-muscle invasive bladder cancer can be considered a curative option, but the associated risk in comorbid patients is leading researchers to further explore the option of immunotherapy.